HRP20230417T1 - Kruti oblici i formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamida - Google Patents
Kruti oblici i formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamida Download PDFInfo
- Publication number
- HRP20230417T1 HRP20230417T1 HRP20230417TT HRP20230417T HRP20230417T1 HR P20230417 T1 HRP20230417 T1 HR P20230417T1 HR P20230417T T HRP20230417T T HR P20230417TT HR P20230417 T HRP20230417 T HR P20230417T HR P20230417 T1 HRP20230417 T1 HR P20230417T1
- Authority
- HR
- Croatia
- Prior art keywords
- hyperproliferative disease
- preparation
- treatment
- pyrazin
- imidazo
- Prior art date
Links
- WDENQIQQYWYTPO-IBGZPJMESA-N acalabrutinib Chemical compound CC#CC(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C(=O)NC=2N=CC=CC=2)=C2N1C=CN=C2N WDENQIQQYWYTPO-IBGZPJMESA-N 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 claims 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 19
- 230000003463 hyperproliferative effect Effects 0.000 claims 19
- 239000012458 free base Substances 0.000 claims 10
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims 6
- 230000005540 biological transmission Effects 0.000 claims 3
- 230000005855 radiation Effects 0.000 claims 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 238000001237 Raman spectrum Methods 0.000 claims 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 208000003747 lymphoid leukemia Diseases 0.000 claims 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 238000002329 infrared spectrum Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Claims (14)
1. Pripravak za upotrebu u liječenju hiperproliferativne bolesti odabrane iz skupine koju čine kronična limfocitna leukemija, mala limfocitna leukemija, ne-Hodgkinov limfom, difuzni veliki B-stanični limfom, limfom plaštenih stanica, folikularni limfom, B-stanična limfoproliferativna bolest, akutna B-stanična limfoblastična leukemija i Waldenstromova makroglobulinemija, pri čemu pripravak sadrži slobodnu bazu kristalnog (S)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-N-(piridin-2-il)benzamida pri čemu je slobodna baza kristalnog (S)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-N-(piridin-2-il)benzamida naznačena time što ima prijenos uzorka rendgenske difrakcije praha koji sadrži vrhove kod 6.4, 8.6, 10.5, 11.6, i 15.7 °2θ ± 0.2 °2θ, pri čemu je uzorak rendgenske difrakcije praha dobiven korištenjem izvora Cu-Kα1 zračenja, te se slobodna baza kristalnog (S)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-N-(piridin-2-il)benzamida primjenjuje u dozi od 100 mg dva puta dnevno.
2. Pripravak za upotrebu u liječenju hiperproliferativne bolesti prema patentnom zahtjevu 1, pri čemu je slobodna baza kristalnog (S)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-N-(piridin-2-il)benzamida naznačena time što ima prijenos uzorka rendgenske difrakcije praha koji dalje sadrži vrhove kod 10.9, 12.7, 13.4, 14.3, 14.9, i 18.2 °2θ ± 0.2 °2θ, pri čemu je uzorak rendgenske difrakcije praha dobiven korištenjem izvora Cu-Kα1 zračenja.
3. Pripravak za upotrebu u liječenju hiperproliferativne bolesti prema bilo kojem od patentnih zahtjeva 1 ili 2, pri čemu je slobodna baza kristalnog (S)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-N-(piridin-2-il)benzamida naznačena time što ima prijenos uzorka rendgenske difrakcije praha koji dalje sadrži jedan ili više vrhova odabranih iz skupine koja se sastoji od 11.3, 15.1, 15.7, 16.1, 17.3, 19.2, 19.4, 19.8, 20.7, 21.1, 21.4, 21.6, 21.9, 22.6, 23.3, 23.6, 24.9, 25.2, 25.4, 25.7, 26.1, 26.4, 26.8, 26.9, 27.7, 28.6, 29.1, 29.4, 30.1, 30.5, 31.7, 31.9, 32.2, 32.6, 33.1, 33.4, 34.5, 35.9, 36.1, 36.8, 37.4, 38.1, 38.9, i 39.5 °2θ ± 0.2 °2θ, pri čemu je uzorak rendgenske difrakcije praha dobiven korištenjem izvora Cu-Kα1 zračenja.
4. Pripravak za upotrebu u liječenju hiperproliferativne bolesti prema bilo kojem od patentnih zahtjeva 1 do 3, pri čemu je slobodna baza kristalnog (S)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-N-(piridin-2-il)benzamida naznačena time što ima Ramanov spektar koji sadrži vrhove kod 1620, 1609, 1547, 1514 i 1495 cm-1 ± 2 cm-1.
5. Pripravak za upotrebu u liječenju hiperproliferativne bolesti prema patentnom zahtjevu 4, pri čemu je slobodna baza kristalnog (S)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-N-(piridin-2-il)benzamida naznačena time što ima Ramanov spektar koji dalje sadrži jedan ili više vrhova odabranih iz skupine koja se sastoji od 1680, 1574, 1454, 1433, 1351, 1312, 1255, 1232, 1187, 1046, 995, 706, 406, i 280 cm-1 ± 2 cm-1.
6. Pripravak za upotrebu u liječenju hiperproliferativne bolesti prema bilo kojem od patentnih zahtjeva 1 do 5, pri čemu je slobodna baza kristalnog (S)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-N-(piridin-2-il)benzamida naznačena time što ima infracrveni (IR) spektar koji sadrži vrhove kod 1621, 1608, 1403, 1303 i 764 cm-1 ± 4 cm-1.
7. Pripravak za upotrebu u liječenju hiperproliferativne bolesti prema patentnom zahtjevu 6, pri čemu je slobodna baza kristalnog (S)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-N-(piridin-2-il)benzamida naznačena time što ima IR spektar koji dalje uključuje jedan ili više vrhova odabranih iz skupine koja se sastoji od 3367, 3089, 2246, 1682, 1574, 1514, 1504, 1454, 1428, 1345, 1248, 1194, 1177, 1149, 1109, 1049, 1023, 1003, 947, 900, 858, 842, 816, 734, 729, 701, 689, 665, 623, i 612 cm-1 ± 4 cm-1.
8. Pripravak za upotrebu u liječenju hiperproliferativne bolesti prema bilo kojem od patentnih zahtjeva 1 do 7, pri čemu je slobodna baza kristalnog (S)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-N-(piridin-2-il)benzamida, te je dodatno naznačena nepostojanjem vode u kristalnoj strukturi.
9. Pripravak za upotrebu u liječenju hiperproliferativne bolesti prema bilo kojem od zahtjeva 1 do 9, naznačen time što pripravak nadalje sadrži najmanje jednu farmaceutski prihvatljivu pomoćnu tvar.
10. Pripravak za upotrebu u liječenju hiperproliferativne bolesti prema zahtjevu 9 naznačen time što je hiperproliferativna bolest kronična limfocitna leukemija.
11. Pripravak za upotrebu u liječenju hiperproliferativne bolesti prema zahtjevu 9 naznačen time što je hiperproliferativna bolest limfom plaštenih stanica.
12. Pripravak za upotrebu u liječenju hiperproliferativne bolesti prema zahtjevu 9 naznačen time što je hiperproliferativna bolest difuzni veliki B-stanični limfom.
13. Pripravak za upotrebu u liječenju hiperproliferativne bolesti prema zahtjevu 9, naznačen time što je hiperproliferativna bolest folikularni limfom.
14. Pripravak za upotrebu u liječenju hiperproliferativne bolesti prema zahtjevu 9, naznačen time što je hiperproliferativna bolest Waldenstromova makroglobulinemija.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562188468P | 2015-07-02 | 2015-07-02 | |
US201562271708P | 2015-12-28 | 2015-12-28 | |
EP21182842.1A EP3954690B1 (en) | 2015-07-02 | 2016-07-01 | Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20230417T1 true HRP20230417T1 (hr) | 2023-07-07 |
Family
ID=56363881
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20230417TT HRP20230417T1 (hr) | 2015-07-02 | 2016-07-01 | Kruti oblici i formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamida |
HRP20211511TT HRP20211511T1 (hr) | 2015-07-02 | 2016-07-01 | Čvrsti oblici i formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamida |
HRP20200934TT HRP20200934T1 (hr) | 2015-07-02 | 2020-06-10 | Kruti oblici i formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamida |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20211511TT HRP20211511T1 (hr) | 2015-07-02 | 2016-07-01 | Čvrsti oblici i formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamida |
HRP20200934TT HRP20200934T1 (hr) | 2015-07-02 | 2020-06-10 | Kruti oblici i formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamida |
Country Status (29)
Country | Link |
---|---|
US (6) | US9796721B2 (hr) |
EP (4) | EP3954690B1 (hr) |
JP (3) | JP6829215B2 (hr) |
KR (1) | KR20180048593A (hr) |
CN (2) | CN113480542A (hr) |
AU (3) | AU2016286548B2 (hr) |
CA (1) | CA2991096A1 (hr) |
CL (1) | CL2017003445A1 (hr) |
CY (3) | CY1124519T1 (hr) |
DK (3) | DK3317281T3 (hr) |
ES (3) | ES2946489T3 (hr) |
FI (1) | FI3954690T3 (hr) |
HK (1) | HK1250511A1 (hr) |
HR (3) | HRP20230417T1 (hr) |
HU (3) | HUE056008T2 (hr) |
IL (3) | IL274066B (hr) |
LT (3) | LT3317281T (hr) |
MA (1) | MA50817B1 (hr) |
MD (1) | MD3317281T2 (hr) |
MX (2) | MX2018000179A (hr) |
MY (1) | MY193514A (hr) |
PL (3) | PL3317281T3 (hr) |
PT (3) | PT3954690T (hr) |
RS (3) | RS60411B1 (hr) |
RU (1) | RU2018103913A (hr) |
SG (1) | SG10201913796UA (hr) |
SI (3) | SI3613745T1 (hr) |
WO (1) | WO2017002095A1 (hr) |
ZA (2) | ZA201800329B (hr) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3179991T3 (pl) * | 2014-08-11 | 2022-02-14 | Acerta Pharma B.V. | Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2 |
PT3954690T (pt) | 2015-07-02 | 2023-06-06 | Acerta Pharma Bv | Formas sólidas e formulações de (s)-4-(8-amino-3-(1-(but- 2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n- (piridin-2-il)benzamida |
CN108137605B (zh) * | 2016-10-05 | 2021-07-13 | 杭州领业医药科技有限公司 | Acp-196的晶型及其制备方法和药物组合物 |
WO2018115965A1 (en) * | 2016-12-23 | 2018-06-28 | Acerta Pharma Bv | Solid forms of imidazopyrazine compounds |
WO2018148961A1 (zh) * | 2017-02-20 | 2018-08-23 | 杭州领业医药科技有限公司 | Acp-196盐的晶型、其制备方法、药物组合物和用途 |
SG11201908977SA (en) * | 2017-03-27 | 2019-10-30 | Tesaro Inc | Niraparib formulations |
TWI761476B (zh) | 2017-03-27 | 2022-04-21 | 美商提薩羅有限公司 | 尼拉帕尼(niraparib)組合物 |
WO2018229613A1 (en) * | 2017-06-13 | 2018-12-20 | Dr. Reddy's Laboratories Limited | Solid forms of acalabrutinib and process for preparation thereof |
WO2019041026A1 (en) * | 2017-08-29 | 2019-03-07 | Apotex Inc. | NEW CRYSTALLINE FORMS OF ACALABRUTINIB |
MA50657A (fr) | 2017-09-26 | 2020-08-05 | Tesaro Inc | Formulations de niraparib |
WO2019105359A1 (zh) * | 2017-11-30 | 2019-06-06 | 苏州科睿思制药有限公司 | Acalabrutinib的晶型及其制备方法和用途 |
CN111527089B (zh) * | 2018-01-05 | 2021-03-12 | 苏州科睿思制药有限公司 | Acalabrutinib的新晶型及其制备方法和用途 |
WO2019159097A1 (en) * | 2018-02-14 | 2019-08-22 | Sun Pharmaceutical Industries Limited | Crystalline polymorphic forms of acalabrutinib |
US20210087195A1 (en) * | 2018-04-26 | 2021-03-25 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | New crystal form of acalbrutinib, preparation method therefor and use thereof |
EP3587421A1 (en) | 2018-06-29 | 2020-01-01 | Sandoz AG | Crystalline forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-alpha]pyrazin-1-yl-n-(pyridin-2-yl)benzamide |
WO2020053795A2 (en) | 2018-09-13 | 2020-03-19 | Fresenius Kabi Oncology Ltd. | Process for the preparation of acalabrutinib and its intermediates |
US20220002302A1 (en) * | 2018-09-25 | 2022-01-06 | Cipla Limited | Novel polymorphs of acalabrutinib, a bruton's tyrosine kinase inhibitor |
US20220153744A1 (en) | 2019-03-27 | 2022-05-19 | Assia Chemical Industries Ltd. | Solid state forms of acalabrutinib |
WO2020225831A1 (en) * | 2019-05-09 | 2020-11-12 | Msn Laboratories Private Limited, R&D Center | Improved process for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)pyrrolidin-2-yl] imidazo[1,5-a]pyrazin-1-yl)}-n-(pyridine-2-yl)benzamide |
WO2021135346A1 (zh) * | 2019-12-31 | 2021-07-08 | 苏州科睿思制药有限公司 | Acalabrutinib的新晶型及其制备方法和用途 |
WO2021239893A1 (en) | 2020-05-29 | 2021-12-02 | Bend Research, Inc. | Amorphous solid dispersion of acalabrutinib |
BR112022025611A2 (pt) | 2020-06-19 | 2023-01-03 | Acerta Pharma Bv | Formas de dosagem de maleato de acalabrutinibe |
CN112028896A (zh) * | 2020-10-14 | 2020-12-04 | 奥锐特药业(天津)有限公司 | 阿卡替尼的新晶型及其制备方法 |
WO2022153330A1 (en) * | 2021-01-13 | 2022-07-21 | Natco Pharma Limited | Pharmaceutical compositions comprising acalabrutinib |
WO2023014817A1 (en) | 2021-08-03 | 2023-02-09 | Syros Pharmaceuticals, Inc. | Compositions and methods for treating lymphomas with a cdk7 inhibitor in combination with a btk inhibitor |
WO2023205279A1 (en) * | 2022-04-19 | 2023-10-26 | The Johns Hopkins University | Improved raman spectroscopy with the addition of aromatic compounds |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001081031A (ja) | 1999-08-30 | 2001-03-27 | Schering Ag | 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤 |
US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
PL354241A1 (en) | 1999-09-17 | 2003-12-29 | Abbott Gmbh & Co.Kgabbott Gmbh & Co.Kg | Kinase inhibitors as therapeutic agents |
US6998391B2 (en) | 2002-02-07 | 2006-02-14 | Supergen.Inc. | Method for treating diseases associated with abnormal kinase activity |
SG132683A1 (en) | 2003-10-15 | 2007-06-28 | Osi Pharm Inc | Imidazopyrazine tyrosine kinase inhibitors |
AU2005230818B2 (en) | 2004-04-02 | 2010-11-25 | Osi Pharmaceuticals, Inc. | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
ITMI20051231A1 (it) | 2005-06-29 | 2006-12-30 | Pharmaproducts Uk Ltd | Formulazioni farmaceutiche contenenti colostro e calcio folinato per il trattamento delle affezioni del cavo orale |
BRPI0615860B8 (pt) | 2005-09-09 | 2021-05-25 | Labopharm Barbados Ltd | composição farmacêutica de liberação prolongada monolítica sólida |
AU2006316605B2 (en) | 2005-11-17 | 2012-04-26 | Osi Pharmaceuticals, Inc. | Fused bicyclic mTOR inhibitors |
AR057960A1 (es) | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
PE20070855A1 (es) | 2005-12-02 | 2007-10-14 | Bayer Pharmaceuticals Corp | Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas |
EP1996193A2 (en) | 2006-03-13 | 2008-12-03 | OSI Pharmaceuticals, Inc. | Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors |
SI2530083T1 (sl) | 2006-09-22 | 2016-09-30 | Pharmacyclics Llc | Inhibitorji Bruton tirozin kinaze |
ES2562215T3 (es) | 2007-03-28 | 2016-03-03 | Pharmacyclics Llc | Inhibidores de la tirosina quinasa de Bruton |
US8809273B2 (en) | 2007-03-28 | 2014-08-19 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
US8088824B2 (en) * | 2007-08-15 | 2012-01-03 | Reata Pharmaceuticals Inc. | Forms of CDDO methyl ester |
AU2008335469A1 (en) | 2007-12-13 | 2009-06-18 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
US9095592B2 (en) | 2008-11-07 | 2015-08-04 | The Research Foundation For The State University Of New York | Bruton's tyrosine kinase as anti-cancer drug target |
US8299077B2 (en) | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
WO2010126960A1 (en) | 2009-04-29 | 2010-11-04 | Locus Pharmaceuticals, Inc. | Pyrrolotriazine compounds |
CN102918042B (zh) | 2010-02-08 | 2016-03-09 | 默沙东有限责任公司 | 8-甲基-1-苯基-咪唑[1,5-a]吡嗪化合物 |
CN102190594A (zh) * | 2010-03-17 | 2011-09-21 | 上海医药工业研究院 | 阿戈美拉汀氯化氢水合物及其制备方法 |
UY33288A (es) | 2010-03-25 | 2011-10-31 | Glaxosmithkline Llc | Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico |
NZ603643A (en) | 2010-05-31 | 2014-07-25 | Ono Pharmaceutical Co | Purinone derivative |
EP2575818A4 (en) | 2010-06-03 | 2013-11-06 | Pharmacyclics Inc | USE OF INHIBITORS OF BRUTON TYROSINE KINASE (BTK) |
US20120053189A1 (en) | 2010-06-28 | 2012-03-01 | Pharmacyclics, Inc. | Btk inhibitors for the treatment of immune mediated conditions |
ES2770550T3 (es) | 2011-05-17 | 2020-07-02 | Univ California | Inhibidores de quinasa |
WO2013003629A2 (en) | 2011-06-28 | 2013-01-03 | Pharmacyclics, Inc. | Methods and compositions for inhibition of bone resorption |
KR20140048968A (ko) | 2011-07-13 | 2014-04-24 | 파마시클릭스, 인코포레이티드 | 브루톤형 티로신 키나제의 억제제 |
EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
US20140155406A1 (en) | 2011-07-19 | 2014-06-05 | Petrus Antonius De Adrianus Man | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk inhibitors |
DK3689878T3 (da) | 2011-07-19 | 2021-11-08 | Merck Sharp & Dohme | 4-imidazopyridazin-1-yl-benzamider og 4-imidazotriazin-1-yl-benzamider som btk-inhibitorer |
EP2771010A4 (en) | 2011-10-19 | 2015-04-01 | Pharmacyclics Inc | USE OF INHIBITORS OF BRUTON TYROSINE KINASE (BTK) |
US20140212425A1 (en) | 2011-12-05 | 2014-07-31 | Immunomedics, Inc. | Therapeutic use of anti-cd22 antibodies for inducing trogocytosis |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
WO2014114185A1 (en) | 2013-01-23 | 2014-07-31 | Merck Sharp & Dohme Corp. | Btk inhibitors |
KR20160006668A (ko) | 2013-03-14 | 2016-01-19 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 키나제 억제제와 cyp3a4 억제제의 배합물 |
WO2014143807A2 (en) | 2013-03-15 | 2014-09-18 | Stromatt Scott | Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders |
MX369503B (es) | 2013-04-08 | 2019-11-11 | Pharmacyclics Llc | Combinaciones que comprenden ibrutinib y abt-199 para tratar trastornos proliferativos de células b y métodos de uso de las mismas. |
UA119537C2 (uk) | 2013-04-08 | 2019-07-10 | Байєр Фарма Акцієнгезелльшафт | ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ |
WO2015018522A1 (en) | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
WO2015057992A1 (en) * | 2013-10-16 | 2015-04-23 | Izumi Raquel | Btk inhibitors for hematopoietic mobilization |
WO2015083008A1 (en) | 2013-12-05 | 2015-06-11 | Acerta Pharma B.V. | Therapeutic combination of a pi3k inhibitor and a btk inhibitor |
CN105793252B (zh) | 2013-12-13 | 2018-01-30 | 豪夫迈·罗氏有限公司 | 布鲁顿氏酪氨酸激酶抑制剂 |
WO2015110923A2 (en) | 2014-01-21 | 2015-07-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor |
FR3021783B1 (fr) | 2014-06-02 | 2016-05-13 | Morpho | Procede de validation de l'authenticite d'un element du corps humain |
PT3954690T (pt) | 2015-07-02 | 2023-06-06 | Acerta Pharma Bv | Formas sólidas e formulações de (s)-4-(8-amino-3-(1-(but- 2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n- (piridin-2-il)benzamida |
-
2016
- 2016-07-01 PT PT211828421T patent/PT3954690T/pt unknown
- 2016-07-01 MX MX2018000179A patent/MX2018000179A/es unknown
- 2016-07-01 ES ES21182842T patent/ES2946489T3/es active Active
- 2016-07-01 IL IL274066A patent/IL274066B/en unknown
- 2016-07-01 HU HUE19196939A patent/HUE056008T2/hu unknown
- 2016-07-01 HR HRP20230417TT patent/HRP20230417T1/hr unknown
- 2016-07-01 AU AU2016286548A patent/AU2016286548B2/en active Active
- 2016-07-01 EP EP21182842.1A patent/EP3954690B1/en active Active
- 2016-07-01 RS RS20200681A patent/RS60411B1/sr unknown
- 2016-07-01 FI FIEP21182842.1T patent/FI3954690T3/fi active
- 2016-07-01 ES ES19196939T patent/ES2895802T3/es active Active
- 2016-07-01 CN CN202110761102.5A patent/CN113480542A/zh active Pending
- 2016-07-01 LT LTEP16735945.4T patent/LT3317281T/lt unknown
- 2016-07-01 EP EP19196939.3A patent/EP3613745B1/en active Active
- 2016-07-01 DK DK16735945.4T patent/DK3317281T3/da active
- 2016-07-01 PL PL16735945T patent/PL3317281T3/pl unknown
- 2016-07-01 IL IL293821A patent/IL293821A/en unknown
- 2016-07-01 SI SI201631364T patent/SI3613745T1/sl unknown
- 2016-07-01 PL PL19196939T patent/PL3613745T3/pl unknown
- 2016-07-01 ES ES16735945T patent/ES2797987T3/es active Active
- 2016-07-01 SG SG10201913796UA patent/SG10201913796UA/en unknown
- 2016-07-01 JP JP2017568182A patent/JP6829215B2/ja active Active
- 2016-07-01 EP EP23157244.7A patent/EP4209493A1/en active Pending
- 2016-07-01 MX MX2020014163A patent/MX2020014163A/es unknown
- 2016-07-01 KR KR1020187003310A patent/KR20180048593A/ko not_active Application Discontinuation
- 2016-07-01 US US15/200,875 patent/US9796721B2/en active Active
- 2016-07-01 WO PCT/IB2016/053988 patent/WO2017002095A1/en active Application Filing
- 2016-07-01 RS RS20211291A patent/RS62455B1/sr unknown
- 2016-07-01 PT PT167359454T patent/PT3317281T/pt unknown
- 2016-07-01 EP EP16735945.4A patent/EP3317281B1/en active Active
- 2016-07-01 MY MYPI2017001918A patent/MY193514A/en unknown
- 2016-07-01 MD MDE20180479T patent/MD3317281T2/ro unknown
- 2016-07-01 DK DK19196939.3T patent/DK3613745T3/da active
- 2016-07-01 PL PL21182842.1T patent/PL3954690T3/pl unknown
- 2016-07-01 LT LTEP19196939.3T patent/LT3613745T/lt unknown
- 2016-07-01 RS RS20230367A patent/RS64195B1/sr unknown
- 2016-07-01 PT PT191969393T patent/PT3613745T/pt unknown
- 2016-07-01 DK DK21182842.1T patent/DK3954690T3/da active
- 2016-07-01 MA MA50817A patent/MA50817B1/fr unknown
- 2016-07-01 CN CN201680050713.6A patent/CN108349978B/zh active Active
- 2016-07-01 SI SI201630805T patent/SI3317281T1/sl unknown
- 2016-07-01 HU HUE16735945A patent/HUE049989T2/hu unknown
- 2016-07-01 RU RU2018103913A patent/RU2018103913A/ru unknown
- 2016-07-01 SI SI201631705T patent/SI3954690T1/sl unknown
- 2016-07-01 HR HRP20211511TT patent/HRP20211511T1/hr unknown
- 2016-07-01 LT LTEP21182842.1T patent/LT3954690T/lt unknown
- 2016-07-01 HU HUE21182842A patent/HUE062258T2/hu unknown
- 2016-07-01 CA CA2991096A patent/CA2991096A1/en active Pending
-
2017
- 2017-09-18 US US15/707,508 patent/US10167291B2/en active Active
- 2017-12-28 IL IL256633A patent/IL256633B/en active IP Right Grant
- 2017-12-28 CL CL2017003445A patent/CL2017003445A1/es unknown
-
2018
- 2018-01-17 ZA ZA2018/00329A patent/ZA201800329B/en unknown
- 2018-07-31 HK HK18109886.8A patent/HK1250511A1/zh unknown
- 2018-11-01 US US16/177,927 patent/US10640509B2/en active Active
-
2020
- 2020-01-16 ZA ZA2020/00300A patent/ZA202000300B/en unknown
- 2020-04-30 US US16/863,033 patent/US11059829B2/en active Active
- 2020-06-10 HR HRP20200934TT patent/HRP20200934T1/hr unknown
- 2020-07-02 CY CY20201100611T patent/CY1124519T1/el unknown
- 2020-11-24 AU AU2020277123A patent/AU2020277123B2/en active Active
-
2021
- 2021-01-21 JP JP2021007689A patent/JP7091494B2/ja active Active
- 2021-06-10 US US17/344,233 patent/US20220177476A1/en not_active Abandoned
- 2021-10-19 CY CY20211100904T patent/CY1124815T1/el unknown
-
2022
- 2022-01-27 US US17/586,726 patent/US11820777B2/en active Active
- 2022-06-15 JP JP2022096907A patent/JP2022120156A/ja active Pending
- 2022-12-23 AU AU2022291635A patent/AU2022291635A1/en active Pending
-
2023
- 2023-06-01 CY CY20231100260T patent/CY1126103T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20230417T1 (hr) | Kruti oblici i formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamida | |
PH12021550809A1 (en) | Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate | |
MX2019013574A (es) | Amidas de piridona deuteradas y sus profarmacos como moduladores de los canales de sodio. | |
GEP20217286B (en) | Pyridone amides as modulators of sodium channels | |
SI3157932T1 (en) | Sodium (2R, 5S, 13AR) -7,9-dioxo-10 ((2,4,6-trifluorobenzyl) carbamoyl) -2,3,4,5,7,9,13,13A-octahydro- 5-methanopyrido (1'2 ': 4.5) pyrazino (2,1-B) oxazepine-8-oleate | |
TN2018000335A1 (en) | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide | |
GEP20207082B (en) | Prodrugs of pyridone amides useful as modulators of sodium channels | |
CL2014001529A1 (es) | Compuestos pirazolo[1,5-a]piridina suistituidos, inhibidores del receptor de tropomiosina quinasa (trk); composicion farmaceutica que los comprende; metodo de inhibicion del recetor de tropomiosina quinasa a (trka); y metodo de tratamiento o prevencion del dolor, cancer, restenosis y aterosclerosis, entre otras enfermedades. | |
AR101403A1 (es) | (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridin-3-carboxamida, su purificación para su uso como principio activo farmacéutico, un procedimiento para su preparación y su empleo en el tratamiento de enfermedades cardiovasculares | |
IL295418B1 (en) | Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus | |
HRP20211653T1 (hr) | 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-on, njegove soli i postupci korištenja istih u kombiniranoj terapiji | |
EP3793533C0 (en) | TABLET DOSAGE FORM FOR ORAL ABSORPTION OF ACTIVE INGREDIENTS | |
TN2015000386A1 (en) | Formulations of organic compounds | |
WO2014027981A3 (en) | Effervescent tablet formulations of dapoxetine and a pde5 inhibitor | |
PH12015502420A1 (en) | PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | |
HRP20220517T1 (hr) | Inhibitor btk za upotrebu u liječenju raka |